Please login to the form below
cell and gene therapy
This page shows the latest cell and gene therapy news and features for those working in and with pharma, biotech and healthcare.
NICE plans to widen the net for data it uses in guidance
guidance and allow existing recommendations to be updated more quickly, said the agency. ... That update is intended to take into account developments such as personalised medicine, digitisation of health and use of cell and gene therapy.
Latest news
-
Bluebird bio’s sickle cell gene therapy shows early-study benefit
Closely follows approval of beta thalassaemia therapy Zynteglo. Bluebird bio’s gene therapy for sickle cell disease (SCD), LentiGlobin, has demonstrated significant benefit in a small group of patients treated in ... On the gene therapy front, Bluebird
-
Novartis defends Zolgensma as FDA investigates ‘data manipulation’
Novartis acquired the gene therapy specialist AveXis in April last year and Zolgensma had been subsequently developed by them. ... There had already been concerns over how commercially sustainable the field of cell and gene therapy is, with Zolgensma’s
-
NICE unveils long-awaited review of methodologies
He added: “NICE is undertaking this review at a time of unprecedented change in the healthcare system, where developments such as personalised medicine, digitalisation of health, and use of cell and ... gene therapy, mean products are becoming ever
-
FDA will maintain the pace, vows Woodcock, but warns of skills gap
a potential flood of new cell and gene therapy products. ... Also eyecatching were Woodcock’s comments on two high profile FDA approvals of spinal muscular atrophy (SMA) treatments, Biogen’s Spinraza and Novartis’ gene therapy Zolgensma.
-
Europe urged to adapt faster to gene therapy challenges
European real world evidence (RWE) frameworks, in order to nurture the nascent cell and gene therapy revolution in the region. ... Investment has been flooding into the cell and gene therapy pipeline in that same period, despite the fact that the
More from news
Approximately 41 fully matching, plus 43 partially matching documents found.
Latest Intelligence
-
Gut instincts lead Takeda to GI pipeline success
Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy. ... Takeda’s strategy is to develop GI products that address the highest unmet needs, which includes projects across
-
Delivering the promise of regenerative medicine
The Cell and Gene Therapy Catapult is also continuing to work to bridge the gap between ‘translational’ research and commercialisation. ... to cell and tissue requirements.
-
Assessing the risks in annuity pricing models
The number of companies targeting the development of new cell and gene therapies has risen dramatically in recent years. . ... Despite the challenges, some cell and gene therapy companies have already launched products based on annuity pricing models.
-
25 Women Leaders in UK Healthcare (part 2)
13. SORAYA BEKKALI. Gene therapy pioneer. Cell and gene therapy is definitely the most exciting development in biopharma research, promising breakthroughs and even cures for previously untreatable diseases. ... Eye diseases are at the forefront of the
-
Gene therapy market access Q&A
Jesper Jorgensen, Health Economics and Market Access Manager, Cell and Gene Therapy Catapult gives his personal view on how to get the new therapies to patients. ... Jesper Jorgensen, Health Economics and Market Access Manager, Cell and Gene Therapy
More from intelligence
Approximately 2 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Health comms agency emotive hires new cell and gene therapy leader
Dr Germano Ferrari. His most recent role was as a programme manager at the UK’s Cell and Gene Therapy Catapult where he helped develop commercialisation pathways for several pre-clinical ... Dr Ferrari said “We have now reached a turning point where
-
Weekly industry appointments
GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”
-
Orchard Therapeutics appoints Mark Rothera as CEO
He said: “Now is an exciting time to be joining Orchard as the cell and gene therapy field is advancing successfully. ... The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and
-
Avita Medical appoints CEO
chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and Genetic Therapy Inc. Lou Panaccio, chairman of Avita, said: “Mike’s expertise across the value chain in cell
-
apceth Biopharma appoints Dusan Kosijer as CFO
He said: “I am excited and honoured to be able to contribute to the company that operates successfully for almost 10 years in the fast-moving field of cell and gene ... successful track record as one of the leading CDMOs for complex cell and gene
More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’. ... outcomes. This is truly unprecedented and more involved than previous solutions to the challenges facing a registry. Early
-
Spotlight interview: 15 minutes on medical and scientific writing
A number of current therapeutic approaches – such as gene editing, gene therapy, and stem-cell therapy – were not in existence when many healthcare professionals (HCPs) underwent their training, so there is ... We have correspondingly invested in
-
Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era
the cost curve to accommodate new and expensive cell and gene therapies. In addition to this, insurance plans demand lower co-pays for hospital costs i.e. ... can. Potential methods of payment proposed for expensive cell and gene therapies include:.
-
Event: World Pharma Pricing and Market Access Congress
Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam in March. ... A major focus was the new challenges facing Health Technology Assessment (HTA) organizations in view of the expanding
-
OPEN Health
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’. ... Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era.
More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Novartis builds its case for novel MS treatment ofatumumab
- New study identifies drugs that are safe to use in COVID-19 treatment
- AbbVie, Amgen and Takeda team up for joint COVID-19 trial
- Novavax reports promising phase 1 results for coronavirus vaccine
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Porterhouse Medical Group joins imc group
- Biogen pays Denali $1bn upfront for Parkinson’s disease programme
- Tecentriq combo fails in advanced triple negative breast cancer
- Bristol-Myers Squibb’s revenues rise on Celgene acquisition
- Socially distanced strategising
- Artificial Intelligence in Digital Therapeutics
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
